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Not every gene nominated as a cause of human disease stands the test of time. As additional
data become available, the evidence supporting the pathogenicity of a particular variant within a
gene can be enhanced or diminished.1 The amyotrophic lateral sclerosis (ALS) field, as much as
any other, has been hesitant to address these controversies, leading to uncertainty among the
research community.
In 2013, we published a study reporting that mutations in the MATR3 gene were a cause of
familial ALS.2 That study was based, in part, on a pedigree in which we described p.Phe115Cys
as the pathogenic variant based on exome sequence data obtained from 4 affected individuals.
An additional member of this kindred (known as USALS#3, member III:10) was recently
diagnosed as having ALS. Clinical genetic testing of this individual showed that they did not
carry the MATR3 mutation. Although this individual may be a phenocopy, a more parsimo-
nious explanation was that a different mutation was responsible.
To address this issue, we performed whole-genome sequencing of this amyotrophic lateral
sclerosis-frontotemporal dementia (ALS-FTD) family on an Illumina NovaSeq6000 sequencer
to identify their true causative mutation (figure 1 and table). The participating institutions’
institutional review boards approved the study (clinicaltrials.gov/ct2/show/NCT02014246),
and informed consent was obtained from all subjects or their surrogate decision makers,
according to the Declaration of Helsinki.
Analysis of the sequence data identified 218 variants that were rare and shared across the 5
affected individuals. One variant was located within intron 26 of the KIF5A gene, 14 base pairs
from the start of exon 27 (chr12:57582588G>T, build hg38). Exon 27 withinKIF5A is a known
mutational hotspot underlying familial ALS.3 Exon trap experiments on cDNA obtained from
our proband confirmed that this intronic mutation led to aberrant splicing of the KIF5AmRNA
transcript. The altered transcript sequence was identical to that produced by other mutations in
this intronic region because of skipping of exon 27 (figure 2).3 This family represents the most
extensive kindred ascribed to a KIF5A mutation to date, and the affected individuals display
both the short survival typically associated with ALS and the prolonged survival previously
observed among some patients carrying mutations in this gene (table).3
Discussion
Our previous publication erroneously nominated the p.Phe115Cys variant in MATR3 as the
cause of disease within the USALS#3 kindred based on exome sequencing of affected
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individuals.2 Here, we correct the record to show that an
intronic mutation within the known mutational hotspot of
KIF5A is the actual cause of disease within this ALS-FTD
family. The availability of DNA from an additional affected
member within this pedigree was vital to identifying the
causative mutation correctly. However, advancements within
the genomics field and our understanding of ALS genetics
were similarly crucial to resolving this family. In particular, our
preexisting knowledge concerning KIF5A allowed us to single
out that variant from the list of shared variants.3
Seven members of the kindred (figure 1 and table) developed
executive dysfunction during their ALS illness, demonstrating a
link between mutations in KIF5A and FTD. Mutations in
KIF5A have now been linked to a wide variety of neurode-
generative conditions, including hereditary spastic paraparesis,4
Charcot-Marie-Tooth disease,4 ALS,3 and, more recently, the
KIF5A protein has been implicated as having a role in Alz-
heimer disease.5 These discoveries show the importance of the
kinesin protein complex and axonal transport within neurons.
Aside from being a striking example of pleiotropy within a
single gene, it also suggests that, cumulatively, mutations within
KIF5A may be a significant cause of neurologic disease.
Despite our recent findings, we maintain that mutations in
MATR3 are a cause of familial ALS. The p.Ser85Cys variant
in MATR3 remains the cause of neurologic disease within
the other pedigree (USALS#4), segregating with disease
among 11 affected members across multiple generations.2
Although there is clear muscle involvement within this
family, there is clinical evidence of upper and lower motor
neuron involvement.2 MATR3 protein is present within
neuronal cytoplasmic inclusions of more than half of spo-
radic ALS patients,6 and pathogenic MATR3 mutants
Figure 1 Intronic mutation in KIF5A identified in an ALS-FTD kindred
The upper panel depicts a lollipop plot of KIF5A depicting the location of the intronic mutation identified in the USALS#3 kindred (red) and known mutations
(gray). The chromatograms showmutant alleles from the indicated individuals (mutation is highlighted in pale pink). The pedigree shows the ALS-FTD kindred
carrying the KIF5A intronic mutation (updated from ref 5). Individuals II:6, II:7, III:1, III:9, III:10, III:11 were diagnosed with ALS by neurologists. In addition, III:7
had executive dysfunction consistent with behavioral FTD based on formal neuropsychological testing, whereas III:1 and III:11 were observed to have mild
cognitive impairment. The phenomenology of other individuals was reconstructed based on history from familymembers.Mt =mutant alleles; wt =wild-type
alleles. Genotypes of presumed obligate carriers are in brackets. Arrow denotes proband. ALS = amyotrophic lateral sclerosis.
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display neurotoxicity that is mitigated by cytoplasmic re-
distribution.7 Motor neuron loss and gliosis have been
observed within the spinal cords of transgenic mice over-
expressing mutant p.Ser85Cys MATR3.8 Finally, there are
reports of other MATR3 mutations in patients diagnosed
with ALS.9
In conclusion, we identified an intronic mutation in KIF5A
that segregated with disease in a large, multigenerational
pedigree. Our efforts highlight the rapid advancements that
are taking place in our understanding of the genetic
architecture of ALS and link mutations in KIF5A to cognitive
impairment/frontotemporal dementia.
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Table Clinical features of affected individuals in the USALS#3 kindred
Individual
Clinical features
Diagnosis Site of onset Age at onset Survival
I:1 ALS Lower limb Died at age 47 Prolonged course
II:1 Dementia Cognition NA NA
II:2 ALS NA NA NA
II:3 Dementia Cognition Died at age 84 NA
II:5 ALS-FTD Cognition NA NA
II:6 ALS-FTD Upper limb 70 5 y
II:7 ALS-FTD Upper limb 57 26 y
III:1 ALS-FTD Lower limb 63 5 y
III:9 ALS Upper limb 52 8 y
III:10 ALS Limb 63 1.5 y
III:11 ALS-FTD Bulbar 50 6 y
Abbreviation: ALS = amyotrophic lateral sclerosis.
Figure 2 The intronic mutation alters the splicing of KIF5A
(A) RNA derived from blood (upper panel) from a healthy individual, an ALS patient not carrying the mutation, and individual III-11 carrying the KIF5A intronic
mutation. RT-PCRwas performed using RNA and previously described primers to amplify awild-type (155 bp) splice formextending fromexon 26 to exon 28.3
An extra band was observed at 127 base pairs indicating aberrant splicing in individual III-11 that was not present in the healthy and disease control subjects.
RNA obtained from an IPS cell line (lower panel) derived from fibroblasts of individual III-11 and a control IPS cell line (A18945) showed the same pattern. (B)
Sanger sequence analysis of the 127bp transcript/band observed in the patient confirmed the skipping of exon 27 of KIF5A yielding an out of frame and
extended disrupted C-terminal peptide sequence.3 ALS = amyotrophic lateral sclerosis.
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